These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11744463)

  • 1. Urinary levels of nuclear matrix protein 22 in patients with urinary diversion.
    Ishii T; Okadome A; Takeuchi F; Hiratsuka Y
    Urology; 2001 Dec; 58(6):940-2. PubMed ID: 11744463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy.
    Dong ZL; Lu ZP; Wang HZ; Zhang LY; Wang ZP; Zhang YF; Ma BL
    Urol Int; 2011; 87(4):445-9. PubMed ID: 22056470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
    Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
    Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.
    Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
    J Urol; 1999 Dec; 162(6):1951-6. PubMed ID: 10569545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
    Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P
    Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMP22 in transitional cell carcinoma of the urinary bladder.
    Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
    J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
    Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
    J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
    Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
    Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer.
    Witjes JA; van der Poel HG; van Balken MR; Debruyne FM; Schalken JA
    Eur Urol; 1998; 33(4):387-91. PubMed ID: 9612682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
    Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
    J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
    Kelly JD; Dudderidge TJ; Wollenschlaeger A; Okoturo O; Burling K; Tulloch F; Halsall I; Prevost T; Prevost AT; Vasconcelos JC; Robson W; Leung HY; Vasdev N; Pickard RS; Williams GH; Stoeber K
    PLoS One; 2012; 7(7):e40305. PubMed ID: 22792272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
    BJU Int; 1999 Oct; 84(6):706-13. PubMed ID: 10510120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit?
    Deliveliotis C; Papatsoris A; Chrisofos M; Dellis A; Liakouras C; Skolarikos A
    Urology; 2005 Aug; 66(2):299-304. PubMed ID: 16040096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urinary NMP22 as a new marker in patients with transitional cell carcinoma].
    Muzzonigro G; Minardi D; Galosi AB; Recchioni A; De Sio G; Polito M
    Arch Ital Urol Androl; 1999 Jun; 71(3):171-7. PubMed ID: 10431409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
    Serretta V; Pomara G; Rizzo I; Esposito E
    Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary NMP22 and renal cell carcinoma.
    Huang S; Rhee E; Patel H; Park E; Kaswick J
    Urology; 2000 Feb; 55(2):227-30. PubMed ID: 10688084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
    J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.